Orion Oyj 2009 AR2
The report highlights Orion's successful performance in 2009, with net sales increasing by 8.5% to EUR 771.5 million and operating profit exceeding EUR 200 million for the first time. Key milestones included the re-acquisition of the rights to the heart failure drug Simdax, which expanded Orion's presence in Southern and Central Europe. The company also implemented a new research and development operating model to increase flexibility and efficiency. In terms of sustainability, Orion reduced its environmental impact by significantly lowering the use of harmful solvents at its pharmaceutical plants and decreasing hazardous waste by nearly 19%.
Company: Orion Oyj
Sector: Manufacturing
Country: Finland
Year: 2009
Type: AR2
Pages: 128
Back to company
Orion Oyj
Annual Report
The report highlights Orion's successful performance in 2009, with net sales increasing by 8.5% to EUR 771.5 million and operating profit exceeding EUR 200 million for the first time. Key milestones included the re-acquisition of the rights to the heart failure drug Simdax, which expanded Orion's presence in Southern and Central Europe. The company also implemented a new research and development operating model to increase flexibility and efficiency. In terms of sustainability, Orion reduced its environmental impact by significantly lowering the use of harmful solvents at its pharmaceutical plants and decreasing hazardous waste by nearly 19%.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2009
Reporting Period
Jan 1, 2009 - Dec 31, 2009
Fiscal Year
2009
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Assurance
Assurance Provider
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Employees